MINNEAPOLIS, Feb. 12, 2014 /PRNewswire-USNewswire/ -- DaVita
Clinical Research® (DCR®), a specialty
contract research organization with services spanning the full
spectrum of drug and device development, announced today that it
has entered into an agreement through which Pyxant Labs Inc. will
provide bioanalytical laboratory services for DCR's early clinical
trials.
(Logo:
http://photos.prnewswire.com/prnh/20140212/DC63568LOGO)
"Pyxant's proven track record and overall commitment to high
quality aligns well with our strategic growth objectives for early
clinical research," said Chad
Jaeger, vice president of early clinical research at DCR.
"This collaboration represents another step forward in providing
comprehensive services aimed at accelerating drug development."
Pyxant Labs is a contract research laboratory specializing in
GLP bioanalytical chemistry support for life sciences clients. As
part of the relationship, Pyxant will provide bioanalytical method
development, sample analysis and formulation development for early
clinical trials conducted at DCR's clinical research units.
"We are excited to further extend our collaboration with the
great team at DCR. DCR has built the best clinical research site
that I have toured in the last 10 years. Their operations team at
the site, corporate culture and high ethical approach made a
compelling case for our association," said Maurice Gaubatz, president and CEO of Pyxant
Labs. "Pairing DCR's clinical execution with Pyxant's bioanalytical
services is a winning combination, exactly in line with our
respective core competencies."
To learn more about DCR and upcoming clinical research trials,
visit participateDaVita.com or DCR on Facebook.
DaVita HealthCare Partners, DaVita Clinical Research, and DCR
are trademarks or registered trademarks of DaVita HealthCare
Partners Inc. Pyxant and Pyxant Labs are trademarks or registered
trademarks of Pyxant Labs Inc. All other trademarks are the
property of their respective owners.
About DaVita Clinical Research
DaVita Clinical
Research (DCR), a wholly owned subsidiary of DaVita HealthCare
Partners Inc. (NYSE: DVA), uses its extensive, applied database and
real-world healthcare experience to assist pharmaceutical and
medical device companies in the design, recruitment and completion
of retrospective, prospective pragmatic and clinical trials. DCR's
scientific and clinical expertise spans the lifecycle of product
development with more than 150 client companies. DCR's
Biorepository, Early Clinical Research unit (Phase I-IIa) and
Clinical Development (Phase IIb through post-marketing) network of
physicians and investigative sites, data research, Health Economics
& Outcomes Research, and Medical Communications are focused on
providing world-class research in both complex/specialty
populations and therapeutic areas, and especially in CKD and ESRD
populations. To learn more about DCR, visit
www.davitaclinicalresearch.com.
About Pyxant Labs
Pyxant Labs is a leading
bioanalytical CRO, supporting clinical and non-clinical drug
development programs for pharmaceutical companies. Pyxant develops
bioanalytical assays, validates methods, and assays samples, all in
compliance with FDA regulatory requirements.Pyxant provides
bioanalytical for GLP animal studies through Phase III clinical
development. Our scientific and regulatory leadership, FDA
compliance record, and stable team of scientists have allowed us to
grow at better than 20% per year, from long standing ongoing
relationships with four dozen clients. For more about Pyxant Labs,
visit www.pyxant.com.
Media Contact:
Bianca Violante
Office: (303) 876-6614
Mobile: (443) 417-6044
Bianca.Violante@DaVita.com
SOURCE DaVita Clinical Research